Greifswald – 19 November 2021 – CHEPLAPHARM increases revenue by 63% year-on-year to €793m for the first nine months of 2021 and has a positive outlook for the annual financial statements
With the publication of the third quarterly financial statements for 2021, CHEPLAPHARM is pleased to announce another quarter of strong growth. Revenue for the first three quarters increased to €793.4m (same period 2020: €486.8m). This allowed CHEPLAPHARM to achieve an EBITDA margin of 61% (with EBITDA of €483.9m; same period 2020: €255.4m) and a gross profit margin of 77% (with gross profit of €610.9m; same period 2020: €332.6m). Positive operating cash flow of €291.4m also underlines the company's profitable business strategy (same period 2020: €181.4m).
CHEPLAPHARM's focus for the year has been on succesfully integrating the 40 products it acquired in the second half of last calendar year (including one acquisition that closed in early January 2021) with a total purchase price of €1.5bn.
Furthermore, CHEPLAPHARM was able to continue its expansion strategy through the successful acquisitions of two additional product portfolios from Astellas and Sanofi. From Sanofi, 10 established products will be transferred to the Cheplapharm portfolio, which will be distributed in over 15 countries. The focus of the five branded products acquired from Astellas is on the treatment of anti-infective medicines and gastroenterology.
With the latest investments, CHEPLAPHARM was able to further diversify its portfolio. Compared to the same period last year, the company gained three new therapeutic areas: Metabolic disorders, neurology and dermatology. CHEPLAPHARM remains highly diversified by therapeutic area, with no single area representing more than 30% of revenue.
With a headcount of 459 (as of 30.09.21), 67% of whom have a scientific background, CHEPLAPHARM is also well positioned to implement its ambitious growth strategy in the coming years.
The financial data presented in this press release has been taken or derived from the unaudited interim condensed consolidated financial statements of Cheplapharm AG as of and for the nine months ended September 30, 2021 and is different from the unaudited interim condensed consolidated financial statements of CHEPLAPHARM Arzneimittel GmbH as of and for the nine months ended September 30, 2020. This release contains forward-looking statements. These statements are based on the current views, expectations, assumptions and information of the management of CHEPLAPHARM Arzneimittel GmbH (the "Company"). Forward-looking statements should not be construed as a promise of future results and developments and involve known and unknown risks and uncertainties. Various factors could cause actual future results, performance or events to differ materially from those described in these statements, and neither the Company nor any other person accepts any responsibility for the accuracy of the opinions expressed in this release or the underlying assumptions. The Company does not assume any obligations to update any forward-looking statements. Moreover, it should be noted that all forward looking statements only speak as of the date of this release and that the Company assumes no obligation, except as required by law, to update any forward-looking statement or to conform any such statement to actual events or developments.
The Company expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this release, whether as a result of new information, future developments or otherwise.
Certain financial data included in the document consists of “non-IFRS financial measures”. These non-IFRS financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with IFRS. You are cautioned not to place undue reliance on any non-IFRS financial measures and ratios included herein.